Communiqués Daxor Corporation

Actions

DXR

US2394671034

Fonds d'investissement à capital fixe

Temps réel estimé Cboe BZX 18:10:32 21/09/2026			Varia. 5j.	Varia. 1 janv.
11,36 ^USD	-2,32%		+1,39%	-21,15%

31/08	Daxor Corporation publie ses résultats pour le semestre clos le 30 juin 2026	CI
30/07	Daxor lance un laboratoire d'analyse sanguine dans l'est du Kansas	MT

Communiqués

08/09	Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference	AQ
01/09	Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter	AQ
30/07	Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas	AQ
07/07	Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas	AQ
02/06	Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor	AQ
28/04	Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis	AQ
08/04	Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center	AQ
26/03	Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026	AQ
17/03	Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions	AQ
10/03	Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress	AQ
09/03	Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026	AQ
04/03	Daxor Corporation Reports 2025 Fiscal Year Results, Operating Revenue Up 45%, Net Asset Value Rises to $9.07 per Share	AQ
03/03	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders	AQ
03/03	Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share	AQ
24/02	Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee	AQ
10/02	Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business	AQ
23/01	Daxor Corporation Announces $9 Million Registered Direct Offering	AQ
25/11	Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer	AQ
21/10/25	Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit	AQ
15/10/25	Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25	AQ
30/09/25	Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA	AQ
23/09/25	Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting	AQ
04/09/25	Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care	AQ
03/09/25	Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
02/09/25	Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter	AQ